Chronic Disease Management Market By Type (Solutions, Services), By Disease Type (Cardiovascular diseases , Diabetes, Cancer, Asthma, Chronic obstructive pulmonary disorders, Others), By End User (Healthcare Providers, Healthcare Payers, Others): Global O

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,840	281 Pages	Allied Market Research	July, 2022	ALMR17464331

Best Price Guarantee
Price	from $3,840
Length	281 Pages
Publisher	Allied Market Research
Published Date	July, 2022
SKU	ALMR17464331

Chronic Disease Management Market By Type (Solutions, Services), By Disease Type (Cardiovascular diseases , Diabetes, Cancer, Asthma, Chronic obstructive pulmonary disorders, Others), By End User (Healthcare Providers, Healthcare Payers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global chronic disease management market was valued at $4,896.69 million in 2021 and is projected to reach $14,875.48 million by 2031, registering a CAGR of 11.8% from 2022 to 2031.

Chronic disease management is an integrated care approach to managing the illness, which includes screenings, check-ups, monitoring and coordinating treatment, and patient education. It can improve the quality of life, while reducing healthcare costs. Chronic disease management programs are designed to improve the health of individuals with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively; thus slowing the progression of those diseases.

The key factors that drive the growth of the market are an increase in awareness regarding the healthcare management service and a rise in the prevalence of chronic diseases such as cancer, heart disease, diabetes, high blood pressure, and others. According to a report published by the World Health Organization, in 2021, non-communicable diseases (NCDs) killed around 41 million people each year, which was 71% of all deaths globally. Moreover, improved services by the service provider have increased the demand for chronic disease management services in the market. The growth in the medical tourism sector and the rise in healthcare IT solutions drive the growth of the chronic disease management market. However, a lack of skilled professionals and high cost of treatment, and high investment in the management system/tools hinder the growth of the market.

The chronic disease management market is segmented on the basis of type, disease type, end user, and region. By type, the market is bifurcated into solutions and services. The solution segment is further classified on the basis of an on-premise solution and a cloud-based solution. On the basis of service, the segment is segmented into educational service, implementation service, and consulting service. On the basis of disease type, the segment is divided into cardiovascular disease, diabetes, cancer, asthma, a chronic obstructive pulmonary disorder, and others. On the basis of end-user, the segment is divided into providers, payers, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the chronic disease management market share in 2021 and is anticipated to remain dominant during the forecast period. The factors, such as favorable regulatory scenario, pressure on healthcare institutions to reduce costs, and rise in trends in healthcare IT, big data and cloud computing, well-established healthcare infrastructure, continuous reforms by governments, and an increase in diseased patient burden are driving the growth of the chronic disease management market in the regions.

For instance, the U.S. government implemented the Affordable Care Act (ACA) for the prevention of diseases and the adoption of healthcare IT. The ACA is expected to boost the growth of the chronic disease management market and create opportunities for population health management service providers to collect and maintain patients’ data.

The key players that operate in the chronic disease management market are WellSky, ZeOmega, Health Catalyst, Cedar Gate Technologies, Cognizant, Pegasystems Inc., Epic Systems Corporation, Hinduja Global Solutions Ltd. (Bengaluru), NXGN Management, LLC, MINES & Associates, Inc., Casenet, LLC, ExlServings Holdings, Inc., cliexa., ScienceSoft USA Corporation, Vivify Health, Inc., Allscripts Healthcare, LLC, Infosys Limited, Medecision, IBM, Altruista Health, TCS Healthcare Technologies, and Koninklijke Philips N.V. (Netherlands

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic disease management market analysis from 2021 to 2031 to identify the prevailing chronic disease management market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the chronic disease management market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global chronic disease management market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Cardiovascular diseases
Diabetes
Cancer
Asthma
Chronic obstructive pulmonary disorders
Others

By Type

Solutions
Services

By End User

Healthcare Providers
Healthcare Payers
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Italy
Spain
Rest of Europe
Germany
France
U.K.
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Koninklijke Philips N.V
Cognizant TriZetto Software Group Inc,
Cedar Gate Technologies
Casenet, LLC
cliexa, Inc
Altruista Health
Infosys Ltd
Pegasystems Inc
Epic Systems Corporation
Hinduja Global Solutions Ltd
NXGN Management, LLC
ExlServings Holdings, Inc
Vivify Health, Inc
Allscripts Healthcare, LLC
Medecision
ZeOmega
Health Catalyst

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key market segments; 1.3.Key benefits to the stakeholders; 1.4.Research Methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Porter’s five forces analysis; 3.4.Top player positioning; 3.5.Market dynamics; 3.5.1.Drivers; 3.5.2.Restraints; 3.5.3.Opportunities; 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE: 4.1 Overview; 4.1.1 Market size and forecast; 4.2 Solutions; 4.2.1 Key market trends, growth factors and opportunities; 4.2.2 Market size and forecast, by region; 4.2.3 Market analysis by country; 4.3 Services; 4.3.1 Key market trends, growth factors and opportunities; 4.3.2 Market size and forecast, by region; 4.3.3 Market analysis by country
CHAPTER 5: CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE: 5.1 Overview; 5.1.1 Market size and forecast; 5.2 Cardiovascular diseases; 5.2.1 Key market trends, growth factors and opportunities; 5.2.2 Market size and forecast, by region; 5.2.3 Market analysis by country; 5.3 Diabetes; 5.3.1 Key market trends, growth factors and opportunities; 5.3.2 Market size and forecast, by region; 5.3.3 Market analysis by country; 5.4 Cancer; 5.4.1 Key market trends, growth factors and opportunities; 5.4.2 Market size and forecast, by region; 5.4.3 Market analysis by country; 5.5 Asthma; 5.5.1 Key market trends, growth factors and opportunities; 5.5.2 Market size and forecast, by region; 5.5.3 Market analysis by country; 5.6 Chronic obstructive pulmonary disorders; 5.6.1 Key market trends, growth factors and opportunities; 5.6.2 Market size and forecast, by region; 5.6.3 Market analysis by country; 5.7 Others; 5.7.1 Key market trends, growth factors and opportunities; 5.7.2 Market size and forecast, by region; 5.7.3 Market analysis by country
CHAPTER 6: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER: 6.1 Overview; 6.1.1 Market size and forecast; 6.2 Healthcare Providers; 6.2.1 Key market trends, growth factors and opportunities; 6.2.2 Market size and forecast, by region; 6.2.3 Market analysis by country; 6.3 Healthcare Payers; 6.3.1 Key market trends, growth factors and opportunities; 6.3.2 Market size and forecast, by region; 6.3.3 Market analysis by country; 6.4 Others; 6.4.1 Key market trends, growth factors and opportunities; 6.4.2 Market size and forecast, by region; 6.4.3 Market analysis by country
CHAPTER 7: CHRONIC DISEASE MANAGEMENT MARKET, BY REGION: 7.1 Overview; 7.1.1 Market size and forecast; 7.2 North America; 7.2.1 Key trends and opportunities; 7.2.2 North America Market size and forecast, by Type; 7.2.3 North America Market size and forecast, by Disease Type; 7.2.4 North America Market size and forecast, by End User; 7.2.5 North America Market size and forecast, by country; 7.2.5.1 U.S.; 7.2.5.1.1 Market size and forecast, by Type; 7.2.5.1.2 Market size and forecast, by Disease Type; 7.2.5.1.3 Market size and forecast, by End User; 7.2.5.2 Canada; 7.2.5.2.1 Market size and forecast, by Type; 7.2.5.2.2 Market size and forecast, by Disease Type; 7.2.5.2.3 Market size and forecast, by End User; 7.2.5.3 Mexico; 7.2.5.3.1 Market size and forecast, by Type; 7.2.5.3.2 Market size and forecast, by Disease Type; 7.2.5.3.3 Market size and forecast, by End User; 7.3 Europe; 7.3.1 Key trends and opportunities; 7.3.2 Europe Market size and forecast, by Type; 7.3.3 Europe Market size and forecast, by Disease Type; 7.3.4 Europe Market size and forecast, by End User; 7.3.5 Europe Market size and forecast, by country; 7.3.5.1 Germany; 7.3.5.1.1 Market size and forecast, by Type; 7.3.5.1.2 Market size and forecast, by Disease Type; 7.3.5.1.3 Market size and forecast, by End User; 7.3.5.2 France; 7.3.5.2.1 Market size and forecast, by Type; 7.3.5.2.2 Market size and forecast, by Disease Type; 7.3.5.2.3 Market size and forecast, by End User; 7.3.5.3 U.K.; 7.3.5.3.1 Market size and forecast, by Type; 7.3.5.3.2 Market size and forecast, by Disease Type; 7.3.5.3.3 Market size and forecast, by End User; 7.3.5.4 Italy; 7.3.5.4.1 Market size and forecast, by Type; 7.3.5.4.2 Market size and forecast, by Disease Type; 7.3.5.4.3 Market size and forecast, by End User; 7.3.5.5 Spain; 7.3.5.5.1 Market size and forecast, by Type; 7.3.5.5.2 Market size and forecast, by Disease Type; 7.3.5.5.3 Market size and forecast, by End User; 7.3.5.6 Rest of Europe; 7.3.5.6.1 Market size and forecast, by Type; 7.3.5.6.2 Market size and forecast, by Disease Type; 7.3.5.6.3 Market size and forecast, by End User; 7.4 Asia-Pacific; 7.4.1 Key trends and opportunities; 7.4.2 Asia-Pacific Market size and forecast, by Type; 7.4.3 Asia-Pacific Market size and forecast, by Disease Type; 7.4.4 Asia-Pacific Market size and forecast, by End User; 7.4.5 Asia-Pacific Market size and forecast, by country; 7.4.5.1 Japan; 7.4.5.1.1 Market size and forecast, by Type; 7.4.5.1.2 Market size and forecast, by Disease Type; 7.4.5.1.3 Market size and forecast, by End User; 7.4.5.2 China; 7.4.5.2.1 Market size and forecast, by Type; 7.4.5.2.2 Market size and forecast, by Disease Type; 7.4.5.2.3 Market size and forecast, by End User; 7.4.5.3 Australia; 7.4.5.3.1 Market size and forecast, by Type; 7.4.5.3.2 Market size and forecast, by Disease Type; 7.4.5.3.3 Market size and forecast, by End User; 7.4.5.4 India; 7.4.5.4.1 Market size and forecast, by Type; 7.4.5.4.2 Market size and forecast, by Disease Type; 7.4.5.4.3 Market size and forecast, by End User; 7.4.5.5 South Korea; 7.4.5.5.1 Market size and forecast, by Type; 7.4.5.5.2 Market size and forecast, by Disease Type; 7.4.5.5.3 Market size and forecast, by End User; 7.4.5.6 Rest Of Asia Pacific; 7.4.5.6.1 Market size and forecast, by Type; 7.4.5.6.2 Market size and forecast, by Disease Type; 7.4.5.6.3 Market size and forecast, by End User; 7.5 LAMEA; 7.5.1 Key trends and opportunities; 7.5.2 LAMEA Market size and forecast, by Type; 7.5.3 LAMEA Market size and forecast, by Disease Type; 7.5.4 LAMEA Market size and forecast, by End User; 7.5.5 LAMEA Market size and forecast, by country; 7.5.5.1 Brazil; 7.5.5.1.1 Market size and forecast, by Type; 7.5.5.1.2 Market size and forecast, by Disease Type; 7.5.5.1.3 Market size and forecast, by End User; 7.5.5.2 Saudi Arabia; 7.5.5.2.1 Market size and forecast, by Type; 7.5.5.2.2 Market size and forecast, by Disease Type; 7.5.5.2.3 Market size and forecast, by End User; 7.5.5.3 South Africa; 7.5.5.3.1 Market size and forecast, by Type; 7.5.5.3.2 Market size and forecast, by Disease Type; 7.5.5.3.3 Market size and forecast, by End User; 7.5.5.4 Rest of LAMEA; 7.5.5.4.1 Market size and forecast, by Type; 7.5.5.4.2 Market size and forecast, by Disease Type; 7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE: 8.1. Introduction; 8.2. Top winning strategies; 8.3. Product Mapping of Top 10 Player; 8.4. Competitive Dashboard; 8.5. Competitive Heatmap; 8.6. Key developments
CHAPTER 9: COMPANY PROFILES: 9.1 Koninklijke Philips N.V; 9.1.1 Company overview; 9.1.2 Company snapshot; 9.1.3 Operating business segments; 9.1.4 Product portfolio; 9.1.5 Business performance; 9.1.6 Key strategic moves and developments; 9.2 Cognizant TriZetto Software Group Inc,; 9.2.1 Company overview; 9.2.2 Company snapshot; 9.2.3 Operating business segments; 9.2.4 Product portfolio; 9.2.5 Business performance; 9.2.6 Key strategic moves and developments; 9.3 Cedar Gate Technologies; 9.3.1 Company overview; 9.3.2 Company snapshot; 9.3.3 Operating business segments; 9.3.4 Product portfolio; 9.3.5 Business performance; 9.3.6 Key strategic moves and developments; 9.4 Casenet, LLC; 9.4.1 Company overview; 9.4.2 Company snapshot; 9.4.3 Operating business segments; 9.4.4 Product portfolio; 9.4.5 Business performance; 9.4.6 Key strategic moves and developments; 9.5 cliexa, Inc; 9.5.1 Company overview; 9.5.2 Company snapshot; 9.5.3 Operating business segments; 9.5.4 Product portfolio; 9.5.5 Business performance; 9.5.6 Key strategic moves and developments; 9.6 Altruista Health; 9.6.1 Company overview; 9.6.2 Company snapshot; 9.6.3 Operating business segments; 9.6.4 Product portfolio; 9.6.5 Business performance; 9.6.6 Key strategic moves and developments; 9.7 Infosys Ltd; 9.7.1 Company overview; 9.7.2 Company snapshot; 9.7.3 Operating business segments; 9.7.4 Product portfolio; 9.7.5 Business performance; 9.7.6 Key strategic moves and developments; 9.8 Pegasystems Inc; 9.8.1 Company overview; 9.8.2 Company snapshot; 9.8.3 Operating business segments; 9.8.4 Product portfolio; 9.8.5 Business performance; 9.8.6 Key strategic moves and developments; 9.9 Epic Systems Corporation; 9.9.1 Company overview; 9.9.2 Company snapshot; 9.9.3 Operating business segments; 9.9.4 Product portfolio; 9.9.5 Business performance; 9.9.6 Key strategic moves and developments; 9.10 Hinduja Global Solutions Ltd; 9.10.1 Company overview; 9.10.2 Company snapshot; 9.10.3 Operating business segments; 9.10.4 Product portfolio; 9.10.5 Business performance; 9.10.6 Key strategic moves and developments; 9.11 NXGN Management, LLC; 9.11.1 Company overview; 9.11.2 Company snapshot; 9.11.3 Operating business segments; 9.11.4 Product portfolio; 9.11.5 Business performance; 9.11.6 Key strategic moves and developments; 9.12 ExlServings Holdings, Inc; 9.12.1 Company overview; 9.12.2 Company snapshot; 9.12.3 Operating business segments; 9.12.4 Product portfolio; 9.12.5 Business performance; 9.12.6 Key strategic moves and developments; 9.13 Vivify Health, Inc; 9.13.1 Company overview; 9.13.2 Company snapshot; 9.13.3 Operating business segments; 9.13.4 Product portfolio; 9.13.5 Business performance; 9.13.6 Key strategic moves and developments; 9.14 Allscripts Healthcare, LLC; 9.14.1 Company overview; 9.14.2 Company snapshot; 9.14.3 Operating business segments; 9.14.4 Product portfolio; 9.14.5 Business performance; 9.14.6 Key strategic moves and developments; 9.15 Medecision; 9.15.1 Company overview; 9.15.2 Company snapshot; 9.15.3 Operating business segments; 9.15.4 Product portfolio; 9.15.5 Business performance; 9.15.6 Key strategic moves and developments; 9.16 ZeOmega; 9.16.1 Company overview; 9.16.2 Company snapshot; 9.16.3 Operating business segments; 9.16.4 Product portfolio; 9.16.5 Business performance; 9.16.6 Key strategic moves and developments; 9.17 Health Catalyst; 9.17.1 Company overview; 9.17.2 Company snapshot; 9.17.3 Operating business segments; 9.17.4 Product portfolio; 9.17.5 Business performance; 9.17.6 Key strategic moves and developments
LIST OF TABLES: TABLE 1. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 2. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR SOLUTIONS, BY REGION, 2021-2031 ($MILLION); TABLE 3. CHRONIC DISEASE MANAGEMENT MARKET FOR SOLUTIONS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 4. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR SERVICES, BY REGION, 2021-2031 ($MILLION); TABLE 5. CHRONIC DISEASE MANAGEMENT MARKET FOR SERVICES, BY COUNTRY, 2021-2031 ($MILLION); TABLE 6. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 7. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR CARDIOVASCULAR DISEASES , BY REGION, 2021-2031 ($MILLION); TABLE 8. CHRONIC DISEASE MANAGEMENT MARKET FOR CARDIOVASCULAR DISEASES , BY COUNTRY, 2021-2031 ($MILLION); TABLE 9. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR DIABETES, BY REGION, 2021-2031 ($MILLION); TABLE 10. CHRONIC DISEASE MANAGEMENT MARKET FOR DIABETES, BY COUNTRY, 2021-2031 ($MILLION); TABLE 11. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR CANCER, BY REGION, 2021-2031 ($MILLION); TABLE 12. CHRONIC DISEASE MANAGEMENT MARKET FOR CANCER, BY COUNTRY, 2021-2031 ($MILLION); TABLE 13. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR ASTHMA, BY REGION, 2021-2031 ($MILLION); TABLE 14. CHRONIC DISEASE MANAGEMENT MARKET FOR ASTHMA, BY COUNTRY, 2021-2031 ($MILLION); TABLE 15. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDERS, BY REGION, 2021-2031 ($MILLION); TABLE 16. CHRONIC DISEASE MANAGEMENT MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 17. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION); TABLE 18. CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 19. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 20. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR HEALTHCARE PROVIDERS, BY REGION, 2021-2031 ($MILLION); TABLE 21. CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 22. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR HEALTHCARE PAYERS, BY REGION, 2021-2031 ($MILLION); TABLE 23. CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 24. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION); TABLE 25. CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 26. CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2021-2031 ($MILLION); TABLE 27. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 28. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 29. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 30. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 31. U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 32. U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 33. U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 34. CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 35. CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 36. CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 37. MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 38. MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 39. MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 40. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 41. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 42. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 43. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 44. GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 45. GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 46. GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 47. FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 48. FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 49. FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 50. U.K. CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 51. U.K. CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 52. U.K. CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 53. ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 54. ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 55. ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 56. SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 57. SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 58. SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 59. REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 60. REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 61. REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 62. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 63. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 64. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 65. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 66. JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 67. JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 68. JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 69. CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 70. CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 71. CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 72. AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 73. AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 74. AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 75. INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 76. INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 77. INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 78. SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 79. SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 80. SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 81. REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 82. REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 83. REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 84. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 85. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 86. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 87. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 88. BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 89. BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 90. BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 91. SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 92. SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 93. SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 94. SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 95. SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 96. SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 97. REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 98. REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION); TABLE 99. REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 100.KONINKLIJKE PHILIPS N.V: COMPANY SNAPSHOT; TABLE 101.KONINKLIJKE PHILIPS N.V: OPERATING SEGMENTS; TABLE 102.KONINKLIJKE PHILIPS N.V: PRODUCT PORTFOLIO; TABLE 103.KONINKLIJKE PHILIPS N.V: NET SALES,; TABLE 104.KONINKLIJKE PHILIPS N.V: KEY STRATERGIES; TABLE 105.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: COMPANY SNAPSHOT; TABLE 106.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: OPERATING SEGMENTS; TABLE 107.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: PRODUCT PORTFOLIO; TABLE 108.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: NET SALES,; TABLE 109.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: KEY STRATERGIES; TABLE 110.CEDAR GATE TECHNOLOGIES: COMPANY SNAPSHOT; TABLE 111.CEDAR GATE TECHNOLOGIES: OPERATING SEGMENTS; TABLE 112.CEDAR GATE TECHNOLOGIES: PRODUCT PORTFOLIO; TABLE 113.CEDAR GATE TECHNOLOGIES: NET SALES,; TABLE 114.CEDAR GATE TECHNOLOGIES: KEY STRATERGIES; TABLE 115.CASENET, LLC: COMPANY SNAPSHOT; TABLE 116.CASENET, LLC: OPERATING SEGMENTS; TABLE 117.CASENET, LLC: PRODUCT PORTFOLIO; TABLE 118.CASENET, LLC: NET SALES,; TABLE 119.CASENET, LLC: KEY STRATERGIES; TABLE 120.CLIEXA, INC: COMPANY SNAPSHOT; TABLE 121.CLIEXA, INC: OPERATING SEGMENTS; TABLE 122.CLIEXA, INC: PRODUCT PORTFOLIO; TABLE 123.CLIEXA, INC: NET SALES,; TABLE 124.CLIEXA, INC: KEY STRATERGIES; TABLE 125.ALTRUISTA HEALTH: COMPANY SNAPSHOT; TABLE 126.ALTRUISTA HEALTH: OPERATING SEGMENTS; TABLE 127.ALTRUISTA HEALTH: PRODUCT PORTFOLIO; TABLE 128.ALTRUISTA HEALTH: NET SALES,; TABLE 129.ALTRUISTA HEALTH: KEY STRATERGIES; TABLE 130.INFOSYS LTD: COMPANY SNAPSHOT; TABLE 131.INFOSYS LTD: OPERATING SEGMENTS; TABLE 132.INFOSYS LTD: PRODUCT PORTFOLIO; TABLE 133.INFOSYS LTD: NET SALES,; TABLE 134.INFOSYS LTD: KEY STRATERGIES; TABLE 135.PEGASYSTEMS INC: COMPANY SNAPSHOT; TABLE 136.PEGASYSTEMS INC: OPERATING SEGMENTS; TABLE 137.PEGASYSTEMS INC: PRODUCT PORTFOLIO; TABLE 138.PEGASYSTEMS INC: NET SALES,; TABLE 139.PEGASYSTEMS INC: KEY STRATERGIES; TABLE 140.EPIC SYSTEMS CORPORATION: COMPANY SNAPSHOT; TABLE 141.EPIC SYSTEMS CORPORATION: OPERATING SEGMENTS; TABLE 142.EPIC SYSTEMS CORPORATION: PRODUCT PORTFOLIO; TABLE 143.EPIC SYSTEMS CORPORATION: NET SALES,; TABLE 144.EPIC SYSTEMS CORPORATION: KEY STRATERGIES; TABLE 145.HINDUJA GLOBAL SOLUTIONS LTD: COMPANY SNAPSHOT; TABLE 146.HINDUJA GLOBAL SOLUTIONS LTD: OPERATING SEGMENTS; TABLE 147.HINDUJA GLOBAL SOLUTIONS LTD: PRODUCT PORTFOLIO; TABLE 148.HINDUJA GLOBAL SOLUTIONS LTD: NET SALES,; TABLE 149.HINDUJA GLOBAL SOLUTIONS LTD: KEY STRATERGIES; TABLE 150.NXGN MANAGEMENT, LLC: COMPANY SNAPSHOT; TABLE 151.NXGN MANAGEMENT, LLC: OPERATING SEGMENTS; TABLE 152.NXGN MANAGEMENT, LLC: PRODUCT PORTFOLIO; TABLE 153.NXGN MANAGEMENT, LLC: NET SALES,; TABLE 154.NXGN MANAGEMENT, LLC: KEY STRATERGIES; TABLE 155.EXLSERVINGS HOLDINGS, INC: COMPANY SNAPSHOT; TABLE 156.EXLSERVINGS HOLDINGS, INC: OPERATING SEGMENTS; TABLE 157.EXLSERVINGS HOLDINGS, INC: PRODUCT PORTFOLIO; TABLE 158.EXLSERVINGS HOLDINGS, INC: NET SALES,; TABLE 159.EXLSERVINGS HOLDINGS, INC: KEY STRATERGIES; TABLE 160.VIVIFY HEALTH, INC: COMPANY SNAPSHOT; TABLE 161.VIVIFY HEALTH, INC: OPERATING SEGMENTS; TABLE 162.VIVIFY HEALTH, INC: PRODUCT PORTFOLIO; TABLE 163.VIVIFY HEALTH, INC: NET SALES,; TABLE 164.VIVIFY HEALTH, INC: KEY STRATERGIES; TABLE 165.ALLSCRIPTS HEALTHCARE, LLC: COMPANY SNAPSHOT; TABLE 166.ALLSCRIPTS HEALTHCARE, LLC: OPERATING SEGMENTS; TABLE 167.ALLSCRIPTS HEALTHCARE, LLC: PRODUCT PORTFOLIO; TABLE 168.ALLSCRIPTS HEALTHCARE, LLC: NET SALES,; TABLE 169.ALLSCRIPTS HEALTHCARE, LLC: KEY STRATERGIES; TABLE 170.MEDECISION: COMPANY SNAPSHOT; TABLE 171.MEDECISION: OPERATING SEGMENTS; TABLE 172.MEDECISION: PRODUCT PORTFOLIO; TABLE 173.MEDECISION: NET SALES,; TABLE 174.MEDECISION: KEY STRATERGIES; TABLE 175.ZEOMEGA: COMPANY SNAPSHOT; TABLE 176.ZEOMEGA: OPERATING SEGMENTS; TABLE 177.ZEOMEGA: PRODUCT PORTFOLIO; TABLE 178.ZEOMEGA: NET SALES,; TABLE 179.ZEOMEGA: KEY STRATERGIES; TABLE 180.HEALTH CATALYST: COMPANY SNAPSHOT; TABLE 181.HEALTH CATALYST: OPERATING SEGMENTS; TABLE 182.HEALTH CATALYST: PRODUCT PORTFOLIO; TABLE 183.HEALTH CATALYST: NET SALES,; TABLE 184.HEALTH CATALYST: KEY STRATERGIES
LIST OF FIGURES: FIGURE 1.CHRONIC DISEASE MANAGEMENT MARKET SEGMENTATION; FIGURE 2.CHRONIC DISEASE MANAGEMENT MARKET,2021-2031; FIGURE 3.CHRONIC DISEASE MANAGEMENT MARKET,2021-2031; FIGURE 4. TOP INVESTMENT POCKETS, BY REGION; FIGURE 5.PORTER FIVE-1; FIGURE 6.PORTER FIVE-2; FIGURE 7.PORTER FIVE-3; FIGURE 8.PORTER FIVE-4; FIGURE 9.PORTER FIVE-5; FIGURE 10.TOP PLAYER POSITIONING; FIGURE 11.CHRONIC DISEASE MANAGEMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 12.CHRONIC DISEASE MANAGEMENT MARKET,BY TYPE,2021(%); FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SOLUTIONS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SERVICES CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 15.CHRONIC DISEASE MANAGEMENT MARKET,BY DISEASE TYPE,2021(%); FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DISEASES CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DIABETES CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CANCER CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ASTHMA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISORDERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 22.CHRONIC DISEASE MANAGEMENT MARKET,BY END USER,2021(%); FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PROVIDERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PAYERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%); FIGURE 26.CHRONIC DISEASE MANAGEMENT MARKET BY REGION,2021; FIGURE 27.U.S. CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 28.CANADA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 29.MEXICO CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 30.GERMANY CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 31.FRANCE CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 32.U.K. CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 33.ITALY CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 34.SPAIN CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 35.REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 36.JAPAN CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 37.CHINA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 38.AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 39.INDIA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 40.SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 41.REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 42.BRAZIL CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 43.SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 44.SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 45.REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION); FIGURE 46. TOP WINNING STRATEGIES, BY YEAR; FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT; FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY; FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 50.COMPETITIVE DASHBOARD; FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS; FIGURE 52.KONINKLIJKE PHILIPS N.V.: NET SALES ,($MILLION); FIGURE 53.COGNIZANT TRIZETTO SOFTWARE GROUP INC,.: NET SALES ,($MILLION); FIGURE 54.CEDAR GATE TECHNOLOGIES.: NET SALES ,($MILLION); FIGURE 55.CASENET, LLC.: NET SALES ,($MILLION); FIGURE 56.CLIEXA, INC.: NET SALES ,($MILLION); FIGURE 57.ALTRUISTA HEALTH.: NET SALES ,($MILLION); FIGURE 58.INFOSYS LTD.: NET SALES ,($MILLION); FIGURE 59.PEGASYSTEMS INC.: NET SALES ,($MILLION); FIGURE 60.EPIC SYSTEMS CORPORATION.: NET SALES ,($MILLION); FIGURE 61.HINDUJA GLOBAL SOLUTIONS LTD.: NET SALES ,($MILLION); FIGURE 62.NXGN MANAGEMENT, LLC.: NET SALES ,($MILLION); FIGURE 63.EXLSERVINGS HOLDINGS, INC.: NET SALES ,($MILLION); FIGURE 64.VIVIFY HEALTH, INC.: NET SALES ,($MILLION); FIGURE 65.ALLSCRIPTS HEALTHCARE, LLC.: NET SALES ,($MILLION); FIGURE 66.MEDECISION.: NET SALES ,($MILLION); FIGURE 67.ZEOMEGA.: NET SALES ,($MILLION); FIGURE 68.HEALTH CATALYST.: NET SALES ,($MILLION)